Liaoning Chengda Biotechnology (688739.SH): The quadrivalent influenza vaccine has obtained a drug registration certificate and passed the drug GMP compliance inspection.

Liaoning Chengda Biotechnology (688739.SH) announces that its wholly owned subsidiary, Liaoning Chengda Biotechnology (Benxi) Co., Ltd. (referred to as "Benxi Subsidiary"), recently received the Drug Registration Certificate for the quadrivalent influenza split vaccine (referred to as "quadrivalent influenza vaccine") issued by the National Medical Products Administration and the "Drug GMP Compliance Inspection Notification" issued by the Liaoning Provincial Medical Products Administration. The scope of the Drug GMP Compliance inspection covers preventive biological products [quadrivalent influenza split vaccine (low-dose injection) (pre-filled)] (influenza seed liquid workshop, influenza seed liquid production line; injection workshop 1, packaging line 2; injection packaging workshop, packaging line 1), and the inspection results meet the requirements of the "Drug Production Quality Management Specification". The Benxi Subsidiary of the company has obtained the Drug Registration Certificate for the quadrivalent influenza vaccine and passed the on-site Drug GMP Compliance inspection, demonstrating that the product has the necessary conditions for compliant and scaled production. The approval of this product will further enrich the company's vaccine product portfolio, enhance the company's business layout in the field of respiratory disease prevention and control, and have significant implications for advancing the subsequent research and development progress and improving research and development capabilities of the company's influenza vaccine series products.